ARQT

Arcutis Biotherapeutics Stock Analysis

AI Rating

Good
  • Quality2/10
  • Growth↑ 7/10
  • Momentum↑ 8/10
Arcutis Biotherapeutics sales and earnings growth
ARQT Growth
Good
  • Revenue Y/Y↑ 129.21%
  • EPS Y/Y↑ 78.92%
  • FCF Y/Y↑ 80.19%
Arcutis Biotherapeutics gross and profit margin trends
ARQT Profitability
Neutral
  • Gross margin ↑ 90.00%
  • EPS margin↓ -13.90%
  • ROIC↓ -9.70%
Arcutis Biotherapeutics net debt vs free cash flow
ARQT Risk
Great
  • Debt / Equity↓ 0.7
  • Debt / FCF↓ 2.0
  • Interest coverage↓ -2.0

Arcutis Biotherapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗